TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26395439

Group type: EXPERIMENTAL
Intervention: School-based health promotion intervention (first stage focused on diet, physical activity, and screen-time behaviour)
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: School-based health promotion intervention (second stage focused only on diet and physical activity)
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1370
Study: 23712446

Group type: EXPERIMENTAL
Intervention: 12 mg betamethasone intravenously
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study: 22108475

Group type: EXPERIMENTAL
Intervention: External valvuloplasty with EVS
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional treatment (ligation or stripping)
Number of subjects: 49
Study: 19576645

Group type: EXPERIMENTAL
Intervention: High-dose concurrent chemo-radiation followed by surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent chemo-radiation
Number of subjects: 0
Study: 12969087

Group type: EXPERIMENTAL
Intervention: Non-erosive gastro-oesophageal reflux disease
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Non-erosive gastro-oesophageal reflux disease with normal acid exposure time
Number of subjects: 65
Study: 15613191

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8672382

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 micrograms
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ephedrine 5 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 38
Study: 1665271

Group type: EXPERIMENTAL
Intervention: Cyclandelate 1600 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6857109

Group type: EXPERIMENTAL
Intervention: (--) Eburnamonine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 2
Study: 3933810

Group type: EXPERIMENTAL
Intervention: Chlorhexidine cleansing before bag application
Number of subjects: 62

Group type: COMPARATOR
Intervention: No cleansing before bag application
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Chlorhexidine cleansing
Number of subjects: 62

Group type: COMPARATOR
Intervention: No cleansing
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Midstream urine specimens
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bagged urine specimens
Number of subjects: 62
Study: 28826957

Group type: EXPERIMENTAL
Intervention: Single-Port Laparoscopic Myomectomy (SP-LM)
Number of subjects: 66
Study: 26478104

Group type: EXPERIMENTAL
Intervention: HA-CMC (sodium hyaluronic acid-carboxymethylcellulose)
Number of subjects: 753
Study: 24944137

Group type: EXPERIMENTAL
Intervention: 3v3
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5v5
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7v7
Number of subjects: 12
Study: 22561098

Group type: EXPERIMENTAL
Intervention: Modified constraint‐induced movement therapy (mCIMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bimanual task‐related training
Number of subjects: 30
Study: 20148744

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 0
Study: 18400976

Group type: EXPERIMENTAL
Intervention: EP HIV-1090 (DNA vaccine)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 16022936

Group type: EXPERIMENTAL
Intervention: In-person decisional balance (IDB)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Written decisional balance (WDB)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Assessment-only control (C)
Number of subjects: 131
Study: 14640387

Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: metformin 850 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 108
Study: 11006052

Group type: EXPERIMENTAL
Intervention: Massachusetts Tobacco Control Program
Number of subjects: 0
Study: 8648205

Group type: EXPERIMENTAL
Intervention: rgp160 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: hepatitis B vaccine (control)
Number of subjects: 0
Study: 1465689

Group type: EXPERIMENTAL
Intervention: HCTZ‐A therapy (50 mg hydrochlorothiazide, 5 mg amiloride)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg) plus HCTZ‐A
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nadolol (120 mg) plus HCTZ‐A
Number of subjects: 11
Study: 6463312

Group type: EXPERIMENTAL
Intervention: 20 mg of methylphenidate (MPD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Night of habituation (N1)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Reference night (placebo) (N2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Night after 20 mg of methylphenidate (MPD) (N3)
Number of subjects: 17
Study: 30652764

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Topical azithromycin
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 132
Study: 29951531

Group type: EXPERIMENTAL
Intervention: Norepinephrine 5 μg/kg/h
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Norepinephrine 10 μg/kg/h
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Norepinephrine 15 μg/kg/h
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 120
Study: 27184585

Group type: EXPERIMENTAL
Intervention: 8-week computer-based brain training programme (Lumosity Inc.®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General information about the brain (control group)
Number of subjects: 0
Study: 25439691

Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg/day)
Number of subjects: 878

Group type: COMPARATOR
Intervention: Erlotinib (150 mg/day)
Number of subjects: 878
Study: 21971754

Group type: EXPERIMENTAL
Intervention: Treadmill with optic flow
Number of subjects: 30
Study: 20736233

Group type: COMPARATOR
Intervention: Epidural analgesia (EDA group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA group) with ropivacaine 150 mg and epinephrine 0.5 mg, ketorolac 30 mg, and morphine 5 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIAiv group) with ropivacaine 150 mg and epinephrine 0.5 mg, ketorolac 30 mg, and morphine 5 mg given intravenously
Number of subjects: 102
Study: 18817485

Group type: EXPERIMENTAL
Intervention: Support Group condition (access to a website with an online mutual support group)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Information Only condition (access to a website containing information about student problems)
Number of subjects: 238
Study: 16022053

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen
Number of subjects: 50
Study: 12447298

Group type: EXPERIMENTAL
Intervention: Tube A (Dobbhoff)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tube B (Freka‐Trelumina)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Upper endoscopy
Number of subjects: 60
Study: 10469687

Group type: EXPERIMENTAL
Intervention: Ganirelix (1.0 or 2.0 mg) administered once daily from stimulation day 6 onwards
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ganirelix (0.0625, 0.125, 0.25, 0.5, 1.0 or 2.0 mg) administered during IVF cycles
Number of subjects: 46
Study: 8694079

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 36

Group type: COMPARATOR
Intervention: Paravaginal repair
Number of subjects: 36
Study: 1910800

Group type: EXPERIMENTAL
Intervention: Stable end‐tidal halothane concentrations of 0.5%
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Stable end‐tidal halothane concentrations of 1.0%
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 13
Study: 6818076

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 28
Study: 31202686

Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions targeting light exposure, fixed meal times, caffeine intake, and exercise; specific details on dosage and duration not provided.
Number of subjects: 0
Study: 28157726

Group type: EXPERIMENTAL
Intervention: β-Alanine (BA) supplementation 6.4 g·d
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 26081010

Group type: EXPERIMENTAL
Intervention: Immediate face-to-face cognitive behavioral therapy (FtF-CBT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Stepped Care treatment model (Psychoeducation, Internet-delivered CBT, and FtF-CBT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Stepped Care treatment model
Number of subjects: 173
Study: 24083670

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) administered intravenously after ex vivo culture expansion with autologous ischemic serum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 21355637

Group type: EXPERIMENTAL
Intervention: TRACK program intervention (3 individual sessions and 1 follow-up phone call)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TRACK program intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 19749674

Group type: EXPERIMENTAL
Intervention: Mini-hysteroscopy with fluid distention
Number of subjects: 930
Study: 17983396

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 14579005

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11359590

Group type: EXPERIMENTAL
Intervention: Test 1: Detection of an audible noise
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Test 2: Detection of endtidal CO2 in the oral cavity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Test 3: Observation of the aneroid manometer dial as the pressure increased
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Test 4: Detection of an audible noise by neck stethoscopy
Number of subjects: 80
Study: 9251160

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7506335

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 0
Study: 3030581

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30574860

Group type: EXPERIMENTAL
Intervention: Enteral bovine lactoferrin (150 mg/kg/day; maximum 300 mg/day)
Number of subjects: 2203

Group type: COMPARATOR
Intervention: Sucrose placebo (same dose)
Number of subjects: 2203

Group type: EXPERIMENTAL
Intervention: Enteral bovine lactoferrin
Number of subjects: 2203

Group type: COMPARATOR
Intervention: Sucrose placebo
Number of subjects: 2203
Study: 26522861

Group type: EXPERIMENTAL
Intervention: Double-layer closure with unlocked first layer
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Double-layer closure with locked first layer
Number of subjects: 81

Group type: COMPARATOR
Intervention: Single-layer closure
Number of subjects: 81
Study: 25843533

Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH) 0.58 mg/0.20 mL injected into palpable cord
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo (only in Collagenase Option for Reduction of Dupuytren I/II)
Number of subjects: 506
Study: 23630033

Group type: EXPERIMENTAL
Intervention: LX4211
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21030144

Group type: EXPERIMENTAL
Intervention: Duloxetine 80mg daily for 3 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 31
Study: 20126853

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone every three weeks (HR group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral vitamins daily (HV and CV groups)
Number of subjects: 62
Study: 18046974

Group type: EXPERIMENTAL
Intervention: Zofenopril 30 mg od (up-titrated to 60 mg od after 4 weeks in non-responders)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril 20 mg od (up-titrated to 40 mg od after 4 weeks in non-responders)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study: 14762880

Group type: EXPERIMENTAL
Intervention: Concurrent chemoirradiation with cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with ifosfamide 1.4 g/m2, 5-fluorouracil 450 mg/m2, and leucovorin 20 mg/m2 daily for 5 days, repeated every 3 weeks for three cycles
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Concurrent chemoirradiation with cisplatin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Concurrent and adjuvant chemotherapy
Number of subjects: 35
Study: 11683693

Group type: EXPERIMENTAL
Intervention: OAAz (amoxicillin 1000 mg b.d. and azithromycin 500 mg on day 1 and 250 mg on days 2-5)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: OCM (clarithromycin 250 mg b.d. and metronidazole 500 mg b.d.)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: OBC (bacampicillin 1200 mg b.d. and clarithromycin 500 mg b.d.)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., and clarithromycin 500 mg b.d.)
Number of subjects: 323
Study: 9215782

Group type: COMPARATOR
Intervention: Accelerated hyperfractionation (AHF) - 0.89 Gy x 3 fractions/day; total dose 61.4 Gy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Accelerated fractionation (AF) RT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperfractionation (HF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-conventional fractionation (non-CF) RT
Number of subjects: 0
Study: 7782974

Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL) for 1 week
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL) for 2 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cefixime (CFIX) for 1 week
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cefixime (CFIX) for 2 weeks
Number of subjects: 62
Study: 2168123

Group type: EXPERIMENTAL
Intervention: Oat-bran cereal diet (25 g oat bran/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Corn flakes diet (control)
Number of subjects: 12
Study: 704919

Group type: EXPERIMENTAL
Intervention: 11-Methyl 16,16 Dimethyl Prostaglandin E2 (TM-PGE) administered orally at dosages of 2.5, 5, 7.5, and 10 microgram/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31314952

Group type: EXPERIMENTAL
Intervention: Nerve Growth Factor (NGF) injections (1 µg, 4 cm interval)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control injections (isotonic-saline)
Number of subjects: 21
Study: 28716283

Group type: EXPERIMENTAL
Intervention: Dalfampridine extended release (D-ER) 10mg tablets twice daily
Number of subjects: 22
Study: 26154829

Group type: EXPERIMENTAL
Intervention: Educational intervention (six education sessions over 3 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 160
Study: 25533024

Group type: EXPERIMENTAL
Intervention: Sapropterin therapy
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 23990508

Group type: EXPERIMENTAL
Intervention: Ligasure™ LF1212
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Harmonic FOCUS(®)
Number of subjects: 245
Study: 20485256

Group type: EXPERIMENTAL
Intervention: Colonoscopic surveillance with random and targeted biopsies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel endoscopic techniques (conventional or virtual chromoendoscopy, confocal laser endomicroscopy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current surveillance strategies based on disease duration
Number of subjects: 0
Study: 18254805

Group type: EXPERIMENTAL
Intervention: Topical treatment based on silymarin/methylsulfonylmethane (S‐MSM) for 1 month
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 16487480

Group type: EXPERIMENTAL
Intervention: High mood induction in euthymic bipolar I disorder group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low mood induction in euthymic bipolar I disorder group
Number of subjects: 96

Group type: COMPARATOR
Intervention: High mood induction in remitted unipolar group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Low mood induction in remitted unipolar group
Number of subjects: 96

Group type: COMPARATOR
Intervention: High mood induction in never-depressed healthy controls
Number of subjects: 96

Group type: COMPARATOR
Intervention: Low mood induction in never-depressed healthy controls
Number of subjects: 96
Study: 12581050

Group type: EXPERIMENTAL
Intervention: Non-enhanced spiral CT (NECT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous pyelography (IVP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both NECT and IVP
Number of subjects: 200
Study: 10807760

Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol plus cyproterone acetate (CA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transdermal 17beta-estradiol plus CA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral CA alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular testosterone esters in transsexual females
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol plus CA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Parenteral testosterone in females
Number of subjects: 30
Study: 9500129

Group type: EXPERIMENTAL
Intervention: Somnium (lorazepam 1 mg + diphenhydramine 25 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: lorazepam (1 mg)
Number of subjects: 44
Study: 8198304

Group type: EXPERIMENTAL
Intervention: Digital block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metacarpal block
Number of subjects: 30
Study: 3286733

Group type: EXPERIMENTAL
Intervention: Food allergy
Number of subjects: 140
Study: 28947180

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 27846888

Group type: EXPERIMENTAL
Intervention: Intramedullary fixation
Number of subjects: 198

Group type: COMPARATOR
Intervention: Extramedullary fixation
Number of subjects: 198
Study: 25707702

Group type: EXPERIMENTAL
Intervention: Central pathology review of prostatic biopsies
Number of subjects: 642
Study: 22939991

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 28
Study: 20587669

Group type: EXPERIMENTAL
Intervention: Simple intervention (prompt letter from the MCO medical director)
Number of subjects: 2357

Group type: EXPERIMENTAL
Intervention: Stepwise intervention (prompt letter from MCO, second letter from primary care physician, counseling from lay health workers)
Number of subjects: 2357

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 2357
Study: 18371557

Group type: EXPERIMENTAL
Intervention: PAC-guided strategy
Number of subjects: 194

Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 194
Study: 16368472

Group type: EXPERIMENTAL
Intervention: Conventional HRT (estradiol (E2) 2 mg/d during 12 days, E2 2 mg/d plus 1 mg/d of norethisterone acetate (NETA) during 10 days, E2 1 mg/d for 6 days)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Long-cycle HRT (two cycles with E2 2 mg/d during 28 days, followed by one cycle of conventional HRT and repeated every 3 months)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 73
Study: 12830471

Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy (1,000 mg daily, adapted to hemoglobin level)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no ribavirin therapy)
Number of subjects: 48
Study: 10953765

Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1.2 mg scopolamine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1.8 mg scopolamine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.75 mg subcutaneous physostigmine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8998818

Group type: EXPERIMENTAL
Intervention: Polysulfone (PS) membrane
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cellulose diacetate (CDA) membrane
Number of subjects: 9
Study: 7890463

Group type: EXPERIMENTAL
Intervention: Reduced Volume Taper (RVT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rest Only Taper (ROT)
Number of subjects: 8
Study: 2953994

Group type: EXPERIMENTAL
Intervention: Tonic vibration reflex (TVR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finger flexion reflex
Number of subjects: 0
Study: 29229613

Group type: EXPERIMENTAL
Intervention: Acupuncture alone
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Acupuncture plus auricular acupuncture (combination treatment)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 224
Study: 26998845

Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS) followed by systemic adjuvant chemotherapy (arm A)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by interval debulking surgery (NACT/IDS) (arm B)
Number of subjects: 110
Study: 24363029

Group type: EXPERIMENTAL
Intervention: Adalimumab 160/80 (160 mg at weeks 0/2, then 40 mg every other week)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Adalimumab 160/80
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 23027232

Group type: EXPERIMENTAL
Intervention: Exercise identity (EXID) and attributional property of controllability
Number of subjects: 224